GPCR 8-K SEC Filing Analysis

Latest settled — T+20d

GPCR ▼ -30.25% at T+20d

NEUTRAL call ✗ call lost -30.25% · α vs SPY -36.29% · entry $54.25 → $37.84

Next anchor: T+60d in 27d

Currently $42.93 · -20.87% from $54.25 entry

Entry anchored
Apr 14, 03:59 PM ET
via Databento tick

T+1d

-1.38%

call -1.38% · α -1.64%

$53.50

settled 8w ago

T+5d

-14.29%

call -14.29% · α -15.92%

$46.50

settled 7w ago

T+20d

-30.25%

call -30.25% · α -36.29%

$37.84

settled 4w ago

T+60d

—

call — · α —

—

in 27d

Price Chart

Loading chart...

Executive Summary

Structure Therapeutics appointed Matthew Lang as Chief Operating Officer and General Counsel, effective April 15, 2026. Lang brings extensive biopharmaceutical leadership experience from roles at Metsera, Lyell Immunopharma, and Myovant Sciences.

Actionable Insight

Monitor Lang's integration into the leadership team and his impact on advancing aleniglipron into Phase 3 development, particularly given his experience with successful drug commercialization at previous companies.

Key Facts

Matthew Lang appointed as COO and General Counsel effective April 15, 2026
Lang previously served as Chief Legal Officer at Metsera and held executive roles at Lyell Immunopharma and Myovant Sciences
Compensation package includes $560,000 base salary, annual bonus target of 40%, and equity grants totaling 454,545 ordinary shares (151,515 ADSs)
Equity awards consist of stock options for 223,776 shares, time-based RSUs for 184,614 shares, and performance-based RSUs for 46,155 shares

Financial Impact

Compensation package with base salary of $560,000 and equity grants valued at approximately $14.8 million based on current stock price

dilutioncompensation

Risk Factors

Integration risk of new executive into existing leadership team
Potential for strategic shifts given Lang's background in commercialization of approved drugs

Market Snapshot

Exchange

Nasdaq

Sector

Pharmaceutical Preparations

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

Document	Accession Number
8-K Filing (Primary)	0001104659-26-043425
Document: tm2611763d1_ex99-1.htm	0001104659-26-043425
Document: 0001104659-26-043425-index-headers.html	0001104659-26-043425
Document: 0001104659-26-043425-index.html	0001104659-26-043425
Document: 0001104659-26-043425.txt	0001104659-26-043425

6 reports for GPCR

T+1T+5T+20T+60

Track record builds as more directional reports settle.

Filters

Reports for GPCR — sortable, filterable
	Type				Now
Jun 11, 2026 1d ago	Institutional Cluster BEARISH ★ 5/10	$42.10 awaiting T+20	awaiting T+20	—	$42.93 (−1.97%)
May 7, 2026 5w ago	8-K MIXED ★ 6/10	$39.10 $37.58	▼ −3.89%	▼ −3.91%	$42.93 (+9.80%)
Apr 27, 2026 6w ago	Press Release NEUTRAL ★ 2/10	$43.56 $39.58	▼ −9.14%	▼ −14.60%	$42.93 (−1.45%)
Apr 15, 2026 8w ago	8-K NEUTRAL ★ 3/10	$54.25 $37.84	▼ −30.25%	▼ −36.29%	$42.93 (−20.87%)
Mar 16, 2026 12w ago	Press Release BULLISH ★ 8/10	$56.65 $53.22	▼ −6.05%	▼ −9.83%	$42.93 (−24.22%)
Feb 28, 2026 15w ago	Institutional Cluster MIXED ★ 6/10	$62.90 $43.94	▼ −30.14%	▼ −22.20%	$42.93 (−31.75%)

US Market Status

Market Closed — Opens Mon (49h 30m)

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access